Publication:
Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza.

dc.contributor.authorBermejo-Martin, Jesus F
dc.contributor.authorOrtiz de Lejarazu, Raul
dc.contributor.authorPumarola, Tomas
dc.contributor.authorRello, Jordi
dc.contributor.authorAlmansa, Raquel
dc.contributor.authorRamírez, Paula
dc.contributor.authorMartin-Loeches, Ignacio
dc.contributor.authorVarillas, David
dc.contributor.authorGallegos, Maria C
dc.contributor.authorSerón, Carlos
dc.contributor.authorMicheloud, Dariela
dc.contributor.authorGomez, Jose Manuel
dc.contributor.authorTenorio-Abreu, Alberto
dc.contributor.authorRamos, María J
dc.contributor.authorMolina, M Lourdes
dc.contributor.authorHuidobro, Samantha
dc.contributor.authorSanchez, Elia
dc.contributor.authorGordón, Mónica
dc.contributor.authorFernández, Victoria
dc.contributor.authorDel Castillo, Alberto
dc.contributor.authorMarcos, Ma Angeles
dc.contributor.authorVillanueva, Beatriz
dc.contributor.authorLópez, Carlos Javier
dc.contributor.authorRodríguez-Domínguez, Mario
dc.contributor.authorGalan, Juan-Carlos
dc.contributor.authorCantón, Rafael
dc.contributor.authorLietor, Aurora
dc.contributor.authorRojo, Silvia
dc.contributor.authorEiros, Jose M
dc.contributor.authorHinojosa, Carmen
dc.contributor.authorGonzalez, Isabel
dc.contributor.authorTorner, Nuria
dc.contributor.authorBanner, David
dc.contributor.authorLeon, Alberto
dc.contributor.authorCuesta, Pablo
dc.contributor.authorRowe, Thomas
dc.contributor.authorKelvin, David J
dc.contributor.authoraffiliation[Bermejo-Martin,JF; Ortiz de Lejarazu,R; Almansa,R; Varillas,D; Rojo,S; Eiros,JM] National Centre of Influenza, Hospital Clínico Universitario de Valladolid, Valladolid, Spain. [Bermejo-Martin,JF; Ortiz de Lejarazu,R; Almansa,R; Varillas,D; Rojo,S; Eiros,JM] Unidad de Investigación en Infección e Inmunidad- Microbiology Service, Hospital Clínico Universitario de Valladolid- IECSCYL, Valladolid, Spain. [Pumarola,T; Marcos,MA] Virology Laboratory, Hospital Clinic de Barcelona, Barcelona. [Rello,J; Martin-Loeches,I] Critical Care Department, Joan XXIII University Hospital-CIBERes Enfermedades Respiratorias-IISPV. Tarragona, Spain. [Ramírez,P; Gordón,M] Critical Care Department, Hospital Universitario La Fe, Spain. [Gallegos,MC; Fernández,V] Microbiology Service, Hospital Son Llatzer, Palma de Mallorca, Spain. [Serón,C] Intensive Care Unit, Hospital General San Jorge, Huesca, Spain. [Micheloud,D; Gomez,JM] Intensive Care Unit & Internal Medicine Service, Hospital Gregorio Marañón, Madrid, Spain. [Tenorio-Abreu,A; Ramos,MJ] Microbiology Service, Hospital Universitario de Canarias, Santa Cruz De Tenerifey, Spain. [Molina,ML] Microbiology Service, Hospital General de La Palma, Breña Alta, Spain. [Huidobro,S] Intensive Care Unit, Hospital Universitario de Canarias, Santa Cruz De Tenerifeý, Spain. [Sanchez,E] Intensive Care Unit, Hospital Virgen del Rocío, Sevilla, Spain. [Del Castillo,A] Intensive Care Unit Service, Hospital Son Llatzer, Palma de Mallorca, Spain. [Villanueva,V; López,CJ] Intensive Care Unit Service, Hospital Lozano Blesa, Zaragoza, Spain. [Rodríguez-Domínguez,M; Galan,JC; Cantón,R] Microbiology Service, Hospital Universitario Ramón y Cajal & CIBERESP, Madrid, Spain. [Lietor,A] Intensive Care Unit, Hospital Universitario Ramón y Cajal, Madrid, Spain. [Hinojosa,C; Gonzalez,I] Infectious Diseases Service, Hospital Clínico Universitario, Valladolid, Spain. [Torner,N] Preventive Medicine Service, Hospital Universitario Valle Hebron & CIBERESP, Barcelona, Spain. [Banner,D; Rowe,T; Kelvin,DJ] Experimental Theraputics Division, University Health Network, Medical Discovery Tower, Toronto,Canada. [Leon,A; Kelvin,DJ] International Institute of Infection and Immunity, Shantou University, Shantou, Guangdong Province, PR China. [Cuesta,P] Intensive Care Unit, Hospital de Villarobredo, Villarrobledo, Spain. [Rowe,T; Kelvin,DJ] Department of Immunology, University of Toronto, Medical Discovery Tower, Toronto, Canada.es
dc.contributor.funderThis work was possible thanks to the financial support obtained from the Ministry of Science of Spain and Consejería de Sanidad Junta de Castilla y León, Programa de Investigación comisionada en gripe, GR09/0021, Programa para favorecer la incorporación de grupos de investigación en las Instituciones del Sistema Nacional de Salud, EMER07/050, and Proyectos en Investigación Sanitaria, PI081236. CIHR, NIH and LKSF-Canada support DJK.
dc.date.accessioned2014-07-02T10:18:51Z
dc.date.available2014-07-02T10:18:51Z
dc.date.issued2009-12-11
dc.descriptionJournal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't;es
dc.description.abstractINTRODUCTION Human host immune response following infection with the new variant of A/H1N1 pandemic influenza virus (nvH1N1) is poorly understood. We utilize here systemic cytokine and antibody levels in evaluating differences in early immune response in both mild and severe patients infected with nvH1N1. METHODS We profiled 29 cytokines and chemokines and evaluated the haemagglutination inhibition activity as quantitative and qualitative measurements of host immune responses in serum obtained during the first five days after symptoms onset, in two cohorts of nvH1N1 infected patients. Severe patients required hospitalization (n = 20), due to respiratory insufficiency (10 of them were admitted to the intensive care unit), while mild patients had exclusively flu-like symptoms (n = 15). A group of healthy donors was included as control (n = 15). Differences in levels of mediators between groups were assessed by using the non parametric U-Mann Whitney test. Association between variables was determined by calculating the Spearman correlation coefficient. Viral load was performed in serum by using real-time PCR targeting the neuraminidase gene. RESULTS Increased levels of innate-immunity mediators (IP-10, MCP-1, MIP-1beta), and the absence of anti-nvH1N1 antibodies, characterized the early response to nvH1N1 infection in both hospitalized and mild patients. High systemic levels of type-II interferon (IFN-gamma) and also of a group of mediators involved in the development of T-helper 17 (IL-8, IL-9, IL-17, IL-6) and T-helper 1 (TNF-alpha, IL-15, IL-12p70) responses were exclusively found in hospitalized patients. IL-15, IL-12p70, IL-6 constituted a hallmark of critical illness in our study. A significant inverse association was found between IL-6, IL-8 and PaO2 in critical patients. CONCLUSIONS While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases. The exact role of Th1 and Th17 mediators in the evolution of nvH1N1 mild and severe disease merits further investigation as to the detrimental or beneficial role these cytokines play in severe illness.es
dc.description.versionYeses
dc.identifier.citationBermejo-Martin JF, Ortiz de Lejarazu R, Pumarola T, Rello J, Almansa R, Ramírez P, et al. Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit Care. 2009; 13(6):R201es
dc.identifier.doi10.1186/cc8208
dc.identifier.essn1466-609X
dc.identifier.issn1364-8535
dc.identifier.pmcPMC2811892
dc.identifier.pmid20003352
dc.identifier.urihttp://hdl.handle.net/10668/1670
dc.journal.titleCritical Care (London, England)
dc.language.isoen
dc.publisherBIOMED CENTRAL LTDes
dc.relation.publisherversionhttp://ccforum.com/content/13/6/R201es
dc.rights.accessRightsopen access
dc.subjectQuimiocinases
dc.subjectCitocinases
dc.subjectCartilla de ADNes
dc.subjectFemeninoes
dc.subjectPruebas de Inhibición de Hemaglutinaciónes
dc.subjectHumanoses
dc.subjectSubtipo H1N1 del Virus de la Influenza Aes
dc.subjectGripe Humanaes
dc.subjectUnidades de Cuidados Intensivoses
dc.subjectTiempo de Internaciónes
dc.subjectMasculinoes
dc.subjectMediana Edades
dc.subjectSelección de Pacientees
dc.subjectARN Virales
dc.subjectÍndice de Severidad de la Enfermedades
dc.subjectCélulas TH1es
dc.subjectCarga Virales
dc.subjectAdultoes
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Cytokines::Chemokineses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Cytokineses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Nucleotides::Polynucleotides::Oligonucleotides::Oligodeoxyribonucleotides::DNA Primerses
dc.subject.meshMedical Subject Headings::Check Tags::Femalees
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Immunologic Tests::Serologic Tests::Hemagglutination Inhibition Testses
dc.subject.meshMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humanses
dc.subject.meshMedical Subject Headings::Organisms::Viruses::RNA Viruses::Orthomyxoviridae::Influenzavirus A::Influenza A virus::Influenza A Virus, H1N1 Subtypees
dc.subject.meshMedical Subject Headings::Diseases::Virus Diseases::RNA Virus Infections::Orthomyxoviridae Infections::Influenza, Humanes
dc.subject.meshMedical Subject Headings::Health Care::Health Care Facilities, Manpower, and Services::Health Facilities::Hospital Units::Intensive Care Unitses
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Patient Care::Hospitalization::Length of Stayes
dc.subject.meshMedical Subject Headings::Check Tags::Malees
dc.subject.meshMedical Subject Headings::Named Groups::Persons::Age Groups::Adult::Middle Agedes
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Methods::Research Design::Patient Selectiones
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Nucleic Acids::RNA::RNA, Virales
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Health Surveys::Health Status Indicators::Severity of Illness Indexes
dc.subject.meshMedical Subject Headings::Anatomy::Cells::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::Lymphocyte Subsets::T-Lymphocyte Subsets::T-Lymphocytes, Helper-Inducer::Th1 Cellses
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Microbiological Techniques::Viral Loades
dc.subject.meshMedical Subject Headings::Named Groups::Persons::Age Groups::Adultes
dc.titleTh1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza.es
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
BermejoMartin_Th1AndTh17.pdf
Size:
356.8 KB
Format:
Adobe Portable Document Format
Description:
Artículo publicado